In a strategic move, Lupin Limited, a prominent player in the Indian pharmaceutical sector, has forged a significant partnership with Amman Pharmaceuticals Industries (Amman Pharma). The collaboration is set to exclusively market and commercialize Ranibizumab biosimilar, a drug analogous to Lucentis, across the Middle East and select territories. These territories include Jordan, Saudi Arabia, UAE, Iraq, Lebanon, and various GCC countries. The primary objective of this collaboration is to enhance patient access to cutting-edge healthcare solutions within the MENA region.
Ranibizumab, a pivotal medication in managing and treating neovascular age-related macular degeneration (AMD) and macular edema, holds the spotlight in this strategic alliance. Administered through direct injection into the eye, this biosimilar functions by impeding the growth of abnormal blood vessels in the eye. This, in turn, reduces leakage and prevents further damage to the retina.
Lupin’s stellar Q2 results have set the stage for this strategic partnership. The company reported an impressive 3.77-fold year-on-year surge in consolidated net profit, reaching Rs 489.6 crore for the July-September quarter of the current financial year. Notably, Lupin’s North America sales for the quarter stood at Rs 18,66.6 crore, marking a substantial 40.4% increase compared to the same quarter the previous year. This segment contributed to 38% of Lupin’s global sales.
Despite a minor dip in share value, trading 1.08% lower at ₹1,191.50 on NSE, Lupin’s strategic moves in the pharmaceutical landscape continue to showcase its commitment to advancing healthcare solutions and expanding its global footprint.
